NIH Targets Long COVID Fatigue in New Trials Testing Potential Treatments
Two phase 2 trials will evaluate the safety and effectiveness of the therapies for symptoms such as fast heart rate, dizziness, and fatigue.
Two phase 2 trials will evaluate the safety and effectiveness of the therapies for symptoms such as fast heart rate, dizziness, and fatigue.
Vanda Pharmaceuticals highlighted updates on regulatory efforts for Hetlioz, focusing on expanding its indications to include the treatment of insomnia and jet lag disorder.
Apnimed unveiled the full results of its MARIPOSA phase 2b trial of AD109, an investigational oral drug for obstructive sleep apnea.
Jazz Pharmaceuticals is pausing its phase 1 clinical trial investigating JZP441, an oral orexin-2 receptor agonist with potential application for the treatment of narcolepsy and other sleep disorders, after reports of adverse effects.
Read MoreThe investigational drug may be able to help patients with Alzheimer’s, Parkinson’s disease, and other central nervous system disorders who often concurrently experience insomnia and/or anxiety, according to the company.
Read MoreNLS Pharmaceutics is exploring strategic alternatives, including the out-licensing of its key asset Mazindol, to maximize shareholder value.
Read MoreCentessa Pharmaceuticals announced third-quarter updates for its narcolepsy drug candidate, ORX750, an orexin receptor 2 agonist.
Read MoreThe FDA has accepted a supplemental new drug application from Vanda Pharmaceuticals for Hetlioz (tasimelteon) in insomnia.
Read MoreThe investigational drug demonstrated a statistically significant and clinically meaningful reduction in excessive daytime sleepiness in adult narcolepsy patients.
Read MoreIn its third-quarter business update, Zevra Therapeutics Inc designated KP1077, its investigational drug in development for idiopathic hypersomnia and narcolepsy, as a pivotal focus area.
Read MoreAxsome Therapeutics reported third-quarter business updates, noting a continued increase in prescriptions for Sunosi and clinical trial progress.
Read MoreHarmony Biosciences reported a 37% increase in net revenue in the third quarter, largely attributed to the growth in patient use of its narcolepsy drug Wakix.
Read MoreA new study unveils the effects of using a standardized and differentiated valerian extract to improve sleep quality and manage occasional anxiety.
Read MoreCentessa Pharmaceuticals is focused on moving ORX750 through IND-enabling studies, obtaining IND clearance, and initiating clinical development of ORX750, which has shown potential to treat narcolepsy in preclinical studies.
Read MoreAlkermes announced preliminary results from a phase 1 study evaluating ALKS 2680, the company’s investigational orexin-2 receptor agonist in development for the treatment of narcolepsy.
Read MoreApnimed will showcase recent findings on its investigational oral obstructive sleep apnea drug, AD109, at World Sleep 2023.
Read MoreTopline results from the INTUNE study of pitolisant for idiopathic hypersomnia revealed that the primary endpoint for excessive daytime sleepiness did not achieve statistical significance against a placebo in the randomized withdrawal phase.
Read MoreResolutionRx Ltd entered into a master services agreement with Ab Initio Pharma to manufacture and test a new dronabinol lipid nanoparticle formulation for OSA.
Read More